DE602004010680D1 - Substituierte imidazopyrimidine zur prävention und behandlung von krebs - Google Patents

Substituierte imidazopyrimidine zur prävention und behandlung von krebs

Info

Publication number
DE602004010680D1
DE602004010680D1 DE602004010680T DE602004010680T DE602004010680D1 DE 602004010680 D1 DE602004010680 D1 DE 602004010680D1 DE 602004010680 T DE602004010680 T DE 602004010680T DE 602004010680 T DE602004010680 T DE 602004010680T DE 602004010680 D1 DE602004010680 D1 DE 602004010680D1
Authority
DE
Germany
Prior art keywords
sub
cancer
treatment
prevention
substituted imidazopyrimidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004010680T
Other languages
English (en)
Other versions
DE602004010680T2 (de
Inventor
Ruiz Juan Lorenzo Catena
Gallemi Carles Farrerons
Serrat Anna Fernandez
Comas Carmen Serra
Lopez Dolors Balsa
Arnal Carmen Lagunas
Roca Carolina Salcedo
Garcia Andres Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
L V A T LAB SA
Laboratorios Salvat SA
Original Assignee
L V A T LAB SA
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L V A T LAB SA, Laboratorios Salvat SA filed Critical L V A T LAB SA
Publication of DE602004010680D1 publication Critical patent/DE602004010680D1/de
Application granted granted Critical
Publication of DE602004010680T2 publication Critical patent/DE602004010680T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004010680T 2003-07-30 2004-07-29 Substituierte imidazopyrimidine zur prävention und behandlung von krebs Expired - Fee Related DE602004010680T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301906 2003-07-30
ES200301906 2003-07-30
PCT/EP2004/008476 WO2005014598A1 (en) 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer

Publications (2)

Publication Number Publication Date
DE602004010680D1 true DE602004010680D1 (de) 2008-01-24
DE602004010680T2 DE602004010680T2 (de) 2009-01-02

Family

ID=34130555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004010680T Expired - Fee Related DE602004010680T2 (de) 2003-07-30 2004-07-29 Substituierte imidazopyrimidine zur prävention und behandlung von krebs

Country Status (14)

Country Link
US (1) US20060189631A1 (de)
EP (1) EP1660500B1 (de)
JP (1) JP2007500160A (de)
KR (1) KR20060034303A (de)
CN (1) CN1860121A (de)
AT (1) ATE380816T1 (de)
AU (1) AU2004263297A1 (de)
BR (1) BRPI0412636A (de)
CA (1) CA2534292A1 (de)
DE (1) DE602004010680T2 (de)
EA (1) EA009038B1 (de)
ES (1) ES2298798T3 (de)
WO (1) WO2005014598A1 (de)
ZA (1) ZA200601706B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200817410A (en) 2006-08-07 2008-04-16 Incyte Corp Triazolotriazines as kinase inhibitors
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
EP2176259B1 (de) * 2007-08-14 2011-03-30 Bayer Schering Pharma Aktiengesellschaft Kondensierte imidazole zur krebsbehandlung
EP2062893A1 (de) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fusionierte Imidazole zur Behandlung von Krebs
CN108586463A (zh) 2008-05-21 2018-09-28 因西特控股公司 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法
AU2010306647B9 (en) 2009-10-16 2016-11-17 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as AKT kinase inhibitors
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
LT3083627T (lt) 2013-12-19 2018-12-27 Novartis Ag [1,2,4]triazolo[1,5-a]pirimidino dariniai kaip protozoano proteasomos inhibitoriai, skirti parazitinių ligų tokių kaip leišmaniozė, gydymui
US10947237B2 (en) 2015-03-11 2021-03-16 BioVersys AG Antimicrobial compounds and methods of making and using the same
CN110312722A (zh) 2016-05-06 2019-10-08 生物验证系统股份公司 抗微生物剂及其制备和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Also Published As

Publication number Publication date
CA2534292A1 (en) 2005-02-17
EP1660500B1 (de) 2007-12-12
EA200600330A1 (ru) 2006-08-25
CN1860121A (zh) 2006-11-08
US20060189631A1 (en) 2006-08-24
EP1660500A1 (de) 2006-05-31
DE602004010680T2 (de) 2009-01-02
EA009038B1 (ru) 2007-10-26
JP2007500160A (ja) 2007-01-11
KR20060034303A (ko) 2006-04-21
ES2298798T3 (es) 2008-05-16
BRPI0412636A (pt) 2006-09-26
AU2004263297A1 (en) 2005-02-17
ATE380816T1 (de) 2007-12-15
WO2005014598A1 (en) 2005-02-17
ZA200601706B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
SE0303180D0 (sv) Novel compounds
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
SE0302232D0 (sv) Novel Compounds
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
DE602006016313D1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
BR0314688A (pt) Novos derivados de piperidina para utilização no tratamento de estados de doença mediados pela quimiocina
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
HK1159614A1 (en) Caspase inhibitors and uses thereof
TW200510317A (en) Caspase inhibitors and uses thereof
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DE60239711D1 (de) Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten zur Behandlung von bipolarer Störung
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE516031T1 (de) Verbindungen gegen krebs
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
GB0412314D0 (en) Compounds
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EA200600115A1 (ru) Производные 2-аминобензойной кислоты

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee